|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/502 | (2006.01) |
| A61K 31/496 | (2013.01) | ||
| A61K 31/4545 | (2006.01) | ||
| A61K 31/495 | (2013.01) | ||
| A61K 31/4985 | (2013.01) | ||
| A61K 31/47 | (2006.01) | ||
| A61K 31/506 | (2013.01) | ||
| A61K 31/675 | (2006.01) | ||
| A61K 31/506 | (2006.01) | ||
| A61K 31/47 | (2013.01) | ||
| A61K 31/519 | (2006.01) | ||
| A61K 31/502 | (2013.01) | ||
| A61K 31/4178 | (2006.01) | ||
| A61K 31/519 | (2013.01) | ||
| A61K 31/44 | (2006.01) | ||
| A61K 31/44 | (2013.01) | ||
| A61K 31/05 | (2006.01) | ||
| A61K 31/4178 | (2013.01) | ||
| A61K 31/496 | (2006.01) | ||
| A61K 31/4545 | (2013.01) | ||
| A61K 31/4985 | (2006.01) | ||
| A61K 31/4439 | (2013.01) | ||
| A61P 9/00 | (2006.01) | ||
| A61K 31/675 | (2013.01) | ||
| A61P 25/24 | (2006.01) | ||
| A61K 31/05 | (2013.01) | ||
| A61K 31/495 | (2006.01) | ||
| A61P 25/24 | (2018.01) | ||
| A61P 35/02 | (2006.01) | ||
| A61P 35/04 | (2018.01) | ||
| A61P 35/04 | (2006.01) | ||
| A61P 35/02 | (2018.01) | ||
| A61P 9/00 | (2018.01) |
| (11) | Number of the document | 3426250 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17897227.9 |
| Date of filing the European patent application | 2017-05-16 | |
| (97) | Date of publication of the European application | 2019-01-16 |
| (45) | Date of publication and mention of the grant of the patent | 2022-03-23 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/032924 |
| Date | 2017-05-16 |
| (87) | Number | WO 2018/212764 |
| Date | 2018-11-22 |
| (72) |
SRINIVASAN, Sundar , US
CHOW, Christina , US
|
| (73) |
Bow River LLC ,
2012 Seadrift Drive, Corona Del Mar, California 92625,
US
|
| (54) | TREATING A PATIENT WITH A CYP3A4 SUBSTRATE DRUG CONTRAINDICATED FOR CONCOMITANT ADMINISTRATION WITH A STRONG CYP3A4 INHIBITOR |
| TREATING A PATIENT WITH A CYP3A4 SUBSTRATE DRUG CONTRAINDICATED FOR CONCOMITANT ADMINISTRATION WITH A STRONG CYP3A4 INHIBITOR |